Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MK-0472 |
| Synonyms | |
| Therapy Description |
MK-0472 inhibits SHP2, which potentially decreases downstream signaling to inhibit tumor cell proliferation and survival (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MK-0472 | MK0472|MK 0427 | SHP2 Inhibitor 21 | MK-0472 inhibits SHP2, which potentially decreases downstream signaling to inhibit tumor cell proliferation and survival (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05853367 | Phase I | MK-0472 + MK-1084 MK-0472 MK-0472 + Pembrolizumab | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | Active, not recruiting | USA | POL | ISR | ESP | CHE | CAN | 1 |